Joined hands with ProEn Therapeutics for radiopharmaceuticals

Became the first Korean pharmaceuticals company to receive the highest ESG rating of ‘AAA’ from MSCI

Presented phase 3 clinical trial results in Northeast Asia at AES

Sealed collaborative research agreement with KIRAMS

Eurofarma submitted NDA for cenobamate in Brazil

Announced roadmap for RPT business development

Signed high-quality radioisotope supply agreement with TerraPower

Sealed a licensing agreement with Full-Life Technologies to develop and commercialize 'FL-091' radiopharmaceutical compound

Cenobamate (XCOPRI^®; ONTOZRY^®) treated over 100,000 patients in the U.S., Europe, Israel, and Canada

Signed a licensing deal with Dong-A ST to commercialize cenobamate in 30 countries, including Korea

Cenobamate (XCOPRI^®) launched in Canada by Paladin labs

Obtaining the approval of the investigational new drug application (IND) from the US FDA for SKL27969, an innovative target anti-cancer drug

Global phase 3 clinical trial for carisbamate with the US FDA

The first Korean company in the pharmaceutical and biotechnology industries to join PSCI

The first announcement of the "social value (SV)" creation results

Licensing out cenobamate to Israel

Licensing out cenobamate to Central and South America, celebrating its expansion into four continents

SKL27969, an innovative target anti-cancer drug, selected for the national new drug development project

The first Korean pharmaceutical company to win the CES 2023 Innovation Award

Winning the “100 Million Dollar Export Tower” award with the single innovative new drug